Novo Nordisk A/S
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
U.S. President Joe Biden speaks about prescription drug costs during an event at NHTI Concord Community College in Concord, New Hampshire, U.S., October 22, 2024. REUTERS/Elizabeth Frantz Elizabeth Frantz | Reuters The Biden administration on Friday unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare, kicking off […]
Read More
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images Eli Lilly cut its revenue guidance on Tuesday as it said demand for its weight loss and diabetes drugs would not meet its lofty expectations. The drugmaker’s […]
Read More
Eli Lilly CEO expects new weight loss pill to be approved next year
David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC Eli Lilly expects its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks told Bloomberg TV on Monday. The company is set to release key late-stage trial data on the drug, orforglipron, by the middle of this year. Eli […]
Read More
High-cost weight loss drugs are sending employers to nutrition counseling in a boost for startups
Packages of weight loss drugs Wegovy, Ozempic and Mounjaro. Picture Alliance | Getty Images A few years ago, when Virta Health founder and CEO Sami Inkinen approached employers about leveraging the company’s nutrition-oriented digital diabetes program for obesity-related weight loss, most companies weren’t ready to commit. Now, more employers are all in on nutritional counseling […]
Read More
Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, CMS says
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Medicare drug plans can now cover Eli Lilly‘s blockbuster obesity drug Zepbound for obstructive sleep apnea, CNBC confirmed on Wednesday. That opens the door for broader access to Zepbound, which is […]
Read More
Eli Lilly’s lead in the obesity race has grown. Its recent stock performance says otherwise
Eli Lilly investors have received some really good news in recent months with a notable exception of how the stock has performed. Shares of Eli Lilly entered Wednesday’s session off nearly 9% since the Oct. 30 close, the day that the drugmaker’s messy third-quarter earnings report sent the stock down 6%. Zoom out further to […]
Read More
Stocks making the biggest moves midday: Edison International, eBay, Getty Images and more
Check out the companies making headlines in midday trading. eBay – Shares jumped 9.7% and touched 52-week highs after announcing that Meta is testing using its listings on Facebook Marketplace . Buyers from Facebook will be redirected to eBay to complete transactions. The gain put the stock on track for its best day since late […]
Read More
Stocks making the biggest moves premarket: SolarEdge, Novo Nordisk, Rigetti, Maplebear and more
Check out the companies making headlines before the bell. SolarEdge Technologies — The solar stock dropped 6%. Citi downgraded SolarEdge to sell from neutral, saying the company faces “stubbornly high” operating expenses despite its restructuring announcement. Shares moved 6.6% and 8% higher on Monday and Tuesday, respectively, after SolarEdge said in a filing Monday it […]
Read More
Want to invest in weight loss drugs? Here’s where UBS thinks they’re headed in 2025
The biopharma sector has been hotly watched among investors over the past two years amid a boost to the industry by the growing popularity of the glucagon-like peptide-1 (GLP-1) drugs used in weight loss treatments. Looking ahead into 2025, however, UBS foresees that the sector “will find it difficult to outperform against a more uncertain […]
Read More
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
Doximity at the New York Stock Exchange for their IPO, June 24, 2021. Source: NYSE If the Covid era marked a boom time for digital health companies, 2024 was the reckoning. In a year that saw the Nasdaq jump 32%, surpassing 20,000 for the first time this month, health tech providers largely suffered. Of 39 […]
Read More